Re: Pssd an odd signal can pssd people keep an eye…
u/drwillpowers
r/DrWillPowers2026-07-15T15:17:25Z
Dr Will Powers’ own statements and theorizing
Summary (paraphrased)
In his PSSD lab-signal request thread, Powers reports that PSSD patients trying zuranolone had horrific effects. His point, he stresses, is not that all PSSD is high-neurosteroid — but that some cases could be, and ignoring the possibility is unwise, especially since androgen and neurosteroid pathways share metabolism (a jam in one jams the other). He notes SSRIs differ in their allopregnanolone effects, that Melcangi's work is PFS-focused, and that he plans a post on the CAR receptor.
Key points (paraphrased)
- Adverse-event signal: horrific effects from zuranolone in some PSSD patients.
- High-neurosteroid PSSD framed as a possible subgroup, not a universal claim.
- Shared androgen/neurosteroid metabolism: a jam in one pathway jams the other.
- SSRIs differ in allopregnanolone effects; Melcangi's published work is PFS-focused.
- Planned post on the CAR receptor (cf. PRH-1511).
Why it’s in the corpus
An adverse-event signal for zuranolone in PSSD and the excess-side subgroup framing — the counterpart to the deficit model. It shows him updating on conflicting community evidence rather than dismissing it.
Context — the post Powers was replying toVerbatim third-party text, shown for context only — not Powers’ statement. Usernames removed.ShowHide
Powers' comment replies to [username removed], who pushed back on the high-neurosteroid framing — citing Melcangi's low-neurosteroid findings and community reports of benefit (not harm) from allopregnanolone-raising interventions such as pregnenolone and zuranolone — in Powers' "PSSD: An odd signal" lab-request thread.
(Parent context recovered from the r.genit.al mirror on 2026-10-09; Powers' comment text itself is from John's user-provided export.)
Some fields on this page come from the release’s Markdown edition, which carries text the JSON edition omits.
Related records
- Peer-reviewed paperPSSD Discord pick
Post-SSRI Sexual Dysfunction (PSSD): A comprehensive review of epidemiology, pathophysiology, and clinical management
Xie, M.; Huang, P.; Wang, S.; Ma, J.; Zeng, Y.; Sun, J. · Journal (SAGE; 2026)
Systematic review (PubMed/Web of Science/Scopus to April 2024) finding persistent symptoms in up to 74% of affected cohorts beyond 6 months; pathophysiology multifactorial — 5-HT1A desensitization, neurosteroid (allopregnanolone) depletion via 5α-reductase…
HTR1APSSD-0032026PFSPSSDCore corpus - Powers · Reddit post
Untitled long-form research update — new model of PFS/PSSD/post-drug syndromes (Sept 2026)
u/drwillpowers · r/DrWillPowers
Powers revised his model: the anhedonia/low-libido subtype of PFS/PSSD is driven by pathological EXCESS — not deficiency — of neurosteroids such as THDOC and androsterone that positively modulate GABA-A, causing downstream neural network remodeling…
DWP-0022026PFSPSSDCore corpus - Video
PSSD and PFS: The Overlooked Syndromes No One Warns You About
Dr. Sanil Rege (consultant psychiatrist) · Dr. Rege · 23:37 (1417s)
PFS/PSSD shared mechanisms; clinical overview; treatment avenues
YT-CZATt5AoQjw2024-07-03PFSPSSDCore corpus